This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Stephen P. Squinto net worth and biography

Stephen Squinto Biography and Net Worth

Director of SpringWorks Therapeutics

Steve joined SpringWorks at the company’s launch in 2017 and served as Acting Head of Research and Development through April 2021. He is currently a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was also a co-founder of Alexion Pharmaceuticals, Inc. and served as its Executive Vice President and Chief Global Operations Officer. Prior to this role, he was Alexion’s Global Head of Research and Development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.

Steve received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.

How do I contact Stephen P. Squinto?: The corporate mailing address for Dr. Squinto and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at [email protected]. Learn More on Stephen P. Squinto's contact information.
Has Stephen P. Squinto been buying or selling shares of SpringWorks Therapeutics?: Stephen P. Squinto has not been actively trading shares of SpringWorks Therapeutics during the last quarter. Learn More on Stephen P. Squinto's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 3 times. They sold a total of 19,818 shares worth more than $886,979.58. The most recent insider tranaction occured on February, 16th when insider Daniel Pichl sold 15,000 shares worth more than $751,500.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 2/16/2024.

Stephen P. Squinto Insider Trading History at SpringWorks Therapeutics

Stephen P. Squinto Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $44.49

$41.75

$45.20

50 Day Range

MA: $47.83

$40.10

$52.50

2 Week Range

Now: $44.49

$18.00

$53.92

Volume

332,488 shs

Average Volume

1,087,692 shs

Market Capitalization

$3.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83